RGPA and KGP were shown to inhibit HIV by binding the HGP44 domain to the HIV envelope glycoprotein (25) and the ability of catalytically active gingipains to bind to the spike protein to inhibit infection should be explored. This evidence concerns the gene ERVW-1 and infection.